<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703363</url>
  </required_header>
  <id_info>
    <org_study_id>MIN-BPD</org_study_id>
    <nct_id>NCT02703363</nct_id>
  </id_info>
  <brief_title>Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression</brief_title>
  <official_title>Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression: A Factorial Design Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbasi Shaheed Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rawalpindi Medical College, Pakistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <brief_summary>
    <textblock>
      Bipolar disorder is a leading cause of disability worldwide. A high proportion of patients
      with bipolar disorder experience persistent depressive symptoms that do not respond to
      standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may
      reduce depressive symptoms. Minocycline is a tetracycline antibiotic with good central
      nervous system (CNS) penetration that has been suggested to be effective as an adjunct drug
      in improving depressive symptoms. Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor,
      has also shown promising results in the treatment of depressive symptoms. In this factorial
      design, double blind, randomised controlled trial the investigators will determine the
      efficacy of minocycline and/or celecoxib as an adjunct to treatment as usual (TAU) in
      patients experiencing a depressive phase of bipolar I or II disorder. The investigators
      hypothesise that augmentation with minocycline and/or celecoxib will lead to an improvement
      in depressive symptoms in participants in comparison with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale scores</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Depression</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Bipolar Depression</condition>
  <condition>Mood Disorders</condition>
  <arm_group>
    <arm_group_label>Minocycline with TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib with TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline and celecoxib with TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with TAU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <arm_group_label>Minocycline with TAU</arm_group_label>
    <arm_group_label>Minocycline and celecoxib with TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Celecoxib with TAU</arm_group_label>
    <arm_group_label>Minocycline and celecoxib with TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo with TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-65 years;

          -  Diagnostic and Statistical Manual-5 (DSM 5) diagnosis of bipolar I or II disorder and
             current major depressive disorder;

          -  Experiencing current depressive symptoms for at least 4 weeks (HAMD-17 score â‰¥18);

          -  Competent and willing to give informed consent;

          -  Taking the current medication for a minimum of 4 week prior to baseline;

          -  Able to take oral medication;

          -  If female, willing to use adequate contraceptive precautions and to have monthly
             pregnancy tests.

        Exclusion Criteria:

          -  Relevant medical illness (HIV, renal, hepatic, cardiac, serious dermatological
             disorders such as exfoliative dermatitis, systemic lupus erythematosis);

          -  Prior history of intolerance to any of the tetracyclines or NSAIDs;

          -  Concomitant penicillin therapy;

          -  Concomitant anticoagulant therapy;

          -  Presence of a seizure disorder;

          -  Currently taking other antibiotics, other NSAIDs, acetazolamide, or methotrexate;

          -  Any change of psychotropic medications within the previous 4 weeks;

          -  Diagnosis of substance abuse (except nicotine or caffeine) or dependence within the
             last 3 months according to DSM-5 criteria;

          -  Pregnant or breast-feeding;

          -  Presence of primary psychotic disorder;

          -  Serious risk of suicide;

          -  Current three or more manic/hypomanic symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dow University of Health Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>69000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raza ur Rahman, FCPS</last_name>
      <phone>+923002579364</phone>
      <email>razaur@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nusrat Husain, MD</last_name>
      <phone>0161-306-7921</phone>
      <email>nusrathusain@btopenworld.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Behavioural Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ajmal Kazmi</last_name>
      <phone>00923213783890</phone>
      <email>kazmiajmal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr Ajmal Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karwan-e-Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>72000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ajmal Kazmi, MRCPsych</last_name>
      <phone>00923213783890</phone>
      <email>kazmiajmal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr Ajmal Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbasi Shaheed Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Muinir Hamirani, FCPS</last_name>
      <phone>+923009272002</phone>
      <email>mmham@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>January 27, 2018</last_update_submitted>
  <last_update_submitted_qc>January 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

